Johnson & Johnson $JNJ Stock Acquired by AlphaCore Capital LLC

Key Points

• AlphaCore Capital increased its Johnson & Johnson stake by 17.7% in the third quarter, adding 8,883 shares to hold 59,109 shares valued at about $15.6 million.
• J&J reported quarterly adjusted earnings of $2.59 per share, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.4 billion. The company set fiscal 2026 EPS guidance of $11.05–$11.15 and declared a $1.34 quarterly dividend.
• Recent pipeline updates included encouraging early results for an investigational prostate cancer combination and a Phase 3 trial success for oral drug candidate ICOTYDE in psoriatic arthritis; the prostate cancer findings are preliminary and require further study.

AlphaCore Capital LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,109 shares of the company's stock after buying an additional 8,883 shares during the quarter. AlphaCore Capital LLC's holdings in Johnson & Johnson were worth $15,649,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $28,000. Navigoe LLC lifted its holdings in Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company's stock valued at $38,000 after purchasing an additional 55 shares during the last quarter. Matrix Trust Co boosted its position in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after buying an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $43,000. Finally, Hanseatic Management Services Inc. bought a new stake in Johnson & Johnson during the third quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Johnson & Johnson Trading Up 2.0%

Shares of JNJ opened at $281.86 on Tuesday. The stock's fifty day simple moving average is $266.18 and its 200-day simple moving average is $248.62. The firm has a market capitalization of $678.53 billion, a PE ratio of 42.71, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.73. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company's revenue was up 5.9% on a year-over-year basis. During the same period last year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson's payout ratio is currently 81.21%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Evercore set a $300.00 price target on Johnson & Johnson in a research report on Tuesday, October 20th. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research report on Wednesday, July 15th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $287.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.